Catalyst Pharmaceuticals (CPRX) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Does the media refer more to BBIO or CPRX?

In the previous week, BridgeBio Pharma had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 9 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.14 beat BridgeBio Pharma's score of 1.08 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BBIO or CPRX?

BridgeBio Pharma currently has a consensus target price of $61.35, suggesting a potential upside of 25.35%. Catalyst Pharmaceuticals has a consensus target price of $33.20, suggesting a potential upside of 58.56%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Catalyst Pharmaceuticals is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	3.00
Catalyst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Do institutionals & insiders believe in BBIO or CPRX?

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Which has stronger earnings and valuation, BBIO or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$221.90M	42.17	-$535.76M	-$4.09	-11.97
Catalyst Pharmaceuticals	$558.50M	4.59	$163.89M	$1.65	12.69

Is BBIO or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 37.36% compared to BridgeBio Pharma's net margin of -329.25%. Catalyst Pharmaceuticals' return on equity of 40.78% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-329.25%	N/A	-85.69%
Catalyst Pharmaceuticals	37.36%	40.78%	35.36%

Which has more volatility & risk, BBIO or CPRX?

BridgeBio Pharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Summary

Catalyst Pharmaceuticals beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.